-
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Location: 60 Leveroni Ct, California, 94949-5746, US | Website: www.ultragenyx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.295B
Cash
763.8M
Avg Qtr Burn
-117.4M
Short % of Float
4.33%
Insider Ownership
3.66%
Institutional Own.
99.09%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DTX301 Details Ornithine transcarbmylase deficiency | Phase 3 Update | |
DTX401 Details Glycogen Storage Disease Type Ia | Phase 3 Update | |
GTX-102 Details Angelman Syndrome | Phase 3 Initiation | |
UX143 (Setrusumab) Details Osteogenesis imperfecta | Phase 2/3 Update | |
UX053 Details Rare diseases, glycogen storage disease type III | Phase 1/2 Data readout | |
UX701 Details Wilson's disease, Rare diseases | Phase 1/2 Data readout | |
UX111 (ABO-102) Details Rare diseases, Sanfilippo Syndrome | Phase 1/2 Update |